Take charge of your health.

Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers. Our mission is to apply this new class of biomarker to both improve assessment of individual cancer risk as well as to dramatically change how we personalize treatment. We are dedicated to making our discoveries fully accessible to all those who can benefit from them.

Joanne Weidhaas, M.D., Ph.D., M.S.M

Founder

Joanne is co-founder of MiraDx and Professor at the David Geffen School of Medicine at UCLA and head of translation research, in the Department of Therapeutic Radiology. Her pioneering research led to the co-discovery of the KRAS-variant, a strong predictor of cancer risk, tumor biology and treatment response. Her passion for empowering individuals to take charge of their health led her to found MiraDx, a genomics company dedicated to giving people and their doctors actionable information to prevent and better treat cancer. Joanne completed her oncology training at Memorial Sloan-Kettering Cancer Center in New York City and previously served as the Chief of the Breast Cancer Radiation Service at Yale Cancer Center and the Section Chief, Breast Cancer, Yale Cancer Center. She took a sabbatical while at Yale and completed a MBM at Stanford University. She has recently moved to UCLA as Division Head, Translational Research. Her dual role as a clinician and researcher enables her to apply genetic breakthroughs to the benefit of her patients. She currently lives in the LA area, with her husband and three children.

Frank Slack, Ph.D.

Co-Founder

Frank is a co-founder of MiraDx and currently the Shields Warren Mallinckrodt Professor, Department of Pathology, and Director of the Institute for RNA Medicine, at BIDMC. His pioneering genetic research led to the discovery of “let-7,” one of the first microRNAs discovered, which he was able to show regulated cancer-causing genes. Dr. Slack is an internationally renown researcher and lecturer on microRNAs, one of the fastest-growing and exciting areas of genetic research.

Board of Directors

Andrew J. Weidhaas

Partner, Goodwin Procter, LLP

A.J. is a partner in and co-chair of Goodwin Procter’s Private Equity Group, as well as a member of its Technology Companies Practice.

Mary Lake Polan, M.D., Ph.D., MPH

Dr. Polan is an Adjunct Professor in the Department of Obstetrics and Gynecology and Reproductive Sciences at Columbia University School of Medicine…

Roy Vagelos M.D.

Chair of the Columbia University School of Physicians and Surgeons Development Campaign and of the board of directors of Regeneron Pharmaceuticals

Dr. Vagelos is former CEO, Chairman and Senior Vice President for Research of Merck.

Richard Gatti, MD, Ph.D.

Laboratory Director, Advisor

Dr. Gatti is laboratory director at MiraDx, and is head of the AT testing program.

Sara Rosenthal, Director, Women’s Health

Director, Women's Health

Sara is the Director of the women’s health program at MiraDx.

Technical Supervisor

Jean is the Laboratory Supervisor at Mira Dx, overseeing its Santa Monica-based lab.

Chris Sweeney

Chris is the Vice-President of Business Development at MiraDx.

Mattias Pitka

Mattias is the Laboratory Lead at MiraDx. He brings experience setting up CLIA and CAP certified laboratories.